Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-18 | Mr. Matthew ShieldsExec. VP of Global Operations | -9,99k | 321,55k | Verkauf | 32,19 | 0,00 | -100,00% |
| 2026-06-11 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -106,56k | 3,63M | Automatic Disposition | 34,10 | 65,62k | -61,89% |
| 2026-06-05 | Dr. Sol J. BarerIndependent Chairman of the Board | 21,74k | 0,00 | Derivative Exercise and Retained Stock | - | 448,01k | 5,10% |
| 2026-06-05 | Dr. Chen LichtensteinIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 19,30k | 301,67% |
| 2026-06-05 | Ms. Rosemary A. CraneIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 127,74k | 12,80% |
| 2026-06-05 | Mr. Perry D. NisenIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 119,81k | 13,76% |
| 2026-06-05 | Mr. Gerald M. LiebermanIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 130,15k | 12,53% |
| 2026-06-05 | Mr. Amir ElsteinIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 2,12M | 0,69% |
| 2026-06-05 | Mr. Roberto Agostino MignoneIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 119,81k | 13,76% |
| 2026-06-05 | Dr. Tal ZaksIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 73,26k | 24,66% |
| 2026-06-05 | Prof. Ronit Satchi-FainaroIndependent Director | 14,49k | 0,00 | Derivative Exercise and Retained Stock | - | 112,40k | 14,80% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | 6,89k | 0,00 | Derivative Exercise and Retained Stock | - | 1,18M | 0,59% |
| 2026-06-05 | Mr. Richard D. FrancisPresident, CEO & Director | -6,15k | 211,36k | Derivative Exercise and Sale | 34,35 | 1,18M | - |
| 2026-06-03 | Mr. Matthew ShieldsExec. VP of Global Operations | -16,20k | 532,33k | Derivative Exercise and Sale | 32,87 | 9,99k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | 44,19k | 0,00 | Derivative Exercise and Retained Stock | - | 44,19k | - |
| 2026-05-14 | Mr. Evan LippmanExec. VP of Business Development | -41,66k | 1,48M | Derivative Exercise and Sale | 35,58 | 44,19k | - |
| 2026-05-14 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -153,25k | 5,46M | Automatic Disposition | 35,61 | 172,18k | -47,09% |
| 2026-05-06 | Mr. Amir WeissSenior VP & CAO | -10,68k | 384,44k | Verkauf | 36,00 | 20,02k | -34,79% |
| 2026-05-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -30,00k | 1,06M | Verkauf | 35,40 | 55,76k | -34,98% |
| 2026-05-01 | Mr. Mark SabagExec. VP of International Markets Commercial | -144,18k | 5,05M | Verkauf | 34,99 | 80,76k | -64,10% |
| 2026-04-30 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -21,26k | 750,62k | Verkauf | 35,31 | 63,65k | -25,04% |
| 2026-03-17 | Mr. Mark SabagExec. VP of International Markets Commercial | -62,10k | 1,87M | Verkauf | 30,14 | 224,94k | -21,64% |
| 2026-03-05 | Mr. Mark SabagExec. VP of International Markets Commercial | 15,72k | 0,00 | Derivative Exercise and Retained Stock | - | 287,04k | 5,80% |
| 2026-03-05 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 19,92k | 0,00 | Derivative Exercise and Retained Stock | - | 325,44k | 6,52% |
| 2026-03-05 | Mr. Amir WeissSenior VP & CAO | 3,54k | 0,00 | Derivative Exercise and Retained Stock | - | 30,70k | 13,02% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | 22,43k | 0,00 | Derivative Exercise and Retained Stock | - | 1,17M | 1,95% |
| 2026-03-05 | Mr. Richard D. FrancisPresident, CEO & Director | -20,03k | 634,16k | Derivative Exercise and Sale | 31,67 | 1,17M | - |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 9,90k | 0,00 | Derivative Exercise and Retained Stock | - | 84,91k | 13,19% |
| 2026-03-05 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -7,92k | 250,94k | Derivative Exercise and Sale | 31,67 | 84,91k | - |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 10,12k | 0,00 | Derivative Exercise and Retained Stock | - | 107,71k | 10,37% |
| 2026-03-05 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -9,53k | 301,89k | Derivative Exercise and Sale | 31,67 | 107,71k | - |
| 2026-03-05 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -17,30k | 547,70k | Derivative Exercise and Sale | 31,67 | 85,76k | - |
| 2026-03-05 | Mr. Placid JoverExec. VP & CHRO | -14,15k | 448,11k | Derivative Exercise and Sale | 31,67 | 6,77k | - |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | 2,45k | 0,00 | Derivative Exercise and Retained Stock | - | 10,91k | 28,99% |
| 2026-03-05 | Mr. Brian SavageInterim Chief Legal Officer | -1,13k | 35,69k | Derivative Exercise and Sale | 31,67 | 10,91k | - |
| 2026-03-05 | Mr. Matthew ShieldsExec. VP of Global Operations | -17,30k | 547,70k | Derivative Exercise and Sale | 31,67 | 9,99k | - |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | 26,83k | 0,00 | Derivative Exercise and Retained Stock | - | 1,15M | 2,39% |
| 2026-03-04 | Mr. Richard D. FrancisPresident, CEO & Director | -23,39k | 759,44k | Derivative Exercise and Sale | 32,46 | 1,15M | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -53,97k | 1,75M | Derivative Exercise and Sale | 32,46 | 85,76k | - |
| 2026-03-04 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -37,37k | 1,23M | Automatic Disposition | 32,95 | 85,76k | -30,35% |
| 2026-03-04 | Mr. Mark SabagExec. VP of International Markets Commercial | 52,11k | 0,00 | Derivative Exercise and Retained Stock | - | 271,32k | 23,77% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 11,97k | 0,00 | Derivative Exercise and Retained Stock | - | 97,59k | 13,99% |
| 2026-03-04 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -11,28k | 366,10k | Derivative Exercise and Sale | 32,46 | 97,59k | - |
| 2026-03-04 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 56,76k | 0,00 | Derivative Exercise and Retained Stock | - | 305,52k | 22,82% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 11,36k | 0,00 | Derivative Exercise and Retained Stock | - | 75,01k | 17,85% |
| 2026-03-04 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -9,10k | 295,36k | Derivative Exercise and Sale | 32,46 | 75,01k | - |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | 5,54k | 0,00 | Derivative Exercise and Retained Stock | - | 8,46k | 189,17% |
| 2026-03-04 | Mr. Brian SavageInterim Chief Legal Officer | -2,68k | 86,84k | Derivative Exercise and Sale | 32,46 | 8,46k | - |
| 2026-03-04 | Mr. Amir WeissSenior VP & CAO | 16,33k | 0,00 | Derivative Exercise and Retained Stock | - | 27,16k | 150,79% |
| 2026-03-03 | Mr. Amir WeissSenior VP & CAO | 5,18k | 0,00 | Derivative Exercise and Retained Stock | - | 10,83k | 91,66% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | 141,48k | 0,00 | Derivative Exercise and Retained Stock | - | 123,13k | -770,96% |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -62,25k | 2,01M | Derivative Exercise and Sale | 32,36 | 123,13k | - |
| 2026-03-03 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -66,74k | 2,16M | Automatic Disposition | 32,36 | 123,13k | -35,15% |
| 2026-03-03 | Mr. Mark SabagExec. VP of International Markets Commercial | 166,38k | 0,00 | Derivative Exercise and Retained Stock | - | 219,21k | 314,94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | 2,19k | 0,00 | Derivative Exercise and Retained Stock | - | 2,93k | 295,94% |
| 2026-03-03 | Mr. Brian SavageInterim Chief Legal Officer | -1,27k | 41,23k | Derivative Exercise and Sale | 32,36 | 2,93k | - |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | 515,61k | 0,00 | Derivative Exercise and Retained Stock | - | 1,12M | 85,12% |
| 2026-03-03 | Mr. Richard D. FrancisPresident, CEO & Director | -442,94k | 14,33M | Derivative Exercise and Sale | 32,36 | 1,12M | - |
| 2026-03-03 | Mr. Eliyahu Sharon KalifExec. VP & CFO | 191,28k | 0,00 | Derivative Exercise and Retained Stock | - | 248,76k | 332,78% |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | 85,62k | 0,00 | Derivative Exercise and Retained Stock | - | 85,62k | - |
| 2026-03-03 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -80,76k | 2,61M | Derivative Exercise and Sale | 32,36 | 85,62k | - |
| 2026-02-26 | Mr. Eliyahu Sharon KalifExec. VP & CFO | -345,81k | 11,63M | Automatic Disposition | 33,64 | 57,48k | -85,75% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | 620,11k | 0,00 | Derivative Exercise and Retained Stock | - | 605,77k | -4.324,64% |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -161,66k | 5,53M | Derivative Exercise and Sale | 34,22 | 605,77k | - |
| 2026-02-15 | Mr. Richard D. FrancisPresident, CEO & Director | -286,12k | 9,79M | Automatic Disposition | 34,22 | 605,77k | -32,08% |
| 2025-12-16 | Mr. Amir WeissSenior VP & CAO | -12,30k | 371,50k | Verkauf | 30,20 | 5,65k | -68,52% |
| 2025-12-16 | Bridger Management LLCUnternehmen | -77,40k | 2,34M | Verkauf | 30,24 | 367,60k | -17,39% |
| 2025-12-09 | Mr. Richard Gordon DaniellExec. VP of European Commercial | -115,47k | 1,19M | Derivative Exercise and Sale | 16,99 - 28,68 | 48,38k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -118,72k | 1,20M | Derivative Exercise and Sale | 18,61 - 28,75 | 52,83k | - |
| 2025-12-09 | Mr. Mark SabagExec. VP of International Markets Commercial | -98,17k | 2,82M | Verkauf | 28,70 | 52,83k | -65,01% |
| 2025-12-02 | Dr. Chen LichtensteinIndependent Director | 4,80k | 0,00 | Derivative Exercise and Retained Stock | - | 4,80k | - |
| 2025-11-26 | Bridger Management LLCUnternehmen | -50,00k | 1,30M | Verkauf | 26,03 | 445,00k | -10,10% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | 35,26k | 0,00 | Derivative Exercise and Retained Stock | - | 63,65k | 124,24% |
| 2025-11-20 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -28,23k | 699,52k | Derivative Exercise and Sale | 24,78 | 63,65k | - |
| 2025-11-14 | Ms. Christine FoxExec. VP of US Commercial & Head of Innovative Franchise | -30,00k | 753,32k | Verkauf | 25,11 | 28,38k | -51,38% |
| 2025-11-06 | Bridger Management LLCUnternehmen | -200,00k | 4,82M | Verkauf | 24,11 | 495,00k | -28,78% |
| 2025-11-06 | Mr. Amir WeissSenior VP & CAO | -12,30k | 300,56k | Verkauf | 24,44 | 17,95k | -40,66% |
| 2025-09-05 | Mr. David R. McavoyInsider | 1,11k | 20,99k | Kauf | 18,86 | 13,03k | 9,34% |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | 6,77k | 0,00 | Derivative Exercise and Retained Stock | - | 6,77k | - |
| 2025-08-01 | Mr. Placid JoverExec. VP & CHRO | -6,05k | 91,75k | Derivative Exercise and Sale | 15,16 | 6,77k | - |
| 2025-08-01 | Dr. Eric A. HughesExec. VP of Global R&D and Chief Medical Officer | -52,74k | 799,44k | Derivative Exercise and Sale | 15,16 | 0,00 | - |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
